Merck & Co., Eisai Launch Up-to-$5.76B Cancer Partnership

Merck & Co. will partner with Eisai to co-develop its marketed cancer treatment Lenvima ®  (lenvatinib mesylate) for additional oncology indications, both alone and in combination with Merck’s Keytruda® (pembrolizumab), through a collaboration that could generate up to $5.76 billion for Eisai, the companies said today.The value of the collaboration represents potentially the second-most-valuable immuno-onocology partnership ever launched—the second time in as many mo